Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Evogene (EVGN)
NASDAQ:EVGN
Holding EVGN?
Track your performance easily
EVGN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.44 - $10.40
Previous Close$1.6
Volume71.45K
Average Volume (3M)275.84K
Market Cap
$8.58M
Enterprise Value-$4.71M
Total Cash (Recent Filing)$31.06M
Total Debt (Recent Filing)$1.14M
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Mar 06, 2025EPS Estimate
-$0.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.45
Shares Outstanding5,079,000
10 Day Avg. Volume122,021
30 Day Avg. Volume275,837
Standard Deviation0.27
R-Squared0.08
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.70
Price to Sales (P/S)1.55
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-6.05
Enterprise Value/Gross Profit-1.19
Enterprise Value/Ebitda0.36
Forecast
1Y Price Target
$5.00Price Target Upside208.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Evogene News
PremiumCompany Announcements
Evogene Sees Revenue Growth and Expands AI Collaboration
Bulls Say, Bears Say
Bulls Say
Commercial SuccessCasterra is believed to be a potential catalyst for the stock via commercial successes, with material value also seen in AgPlenus and Lavie Bio.
Cost ManagementCost controls have appropriately been implemented, leading to a lower than expected operating expense and an EBITDA beat despite lower revenues.
Strategic PartnershipsCasterra’s major seed order from global energy giant Eni is set to be delivered, having been first announced in mid-2023.
Bears Say
Order DelaysDelays in current order delivery and a follow-on order continue to be a material headwind for investors.
Share DilutionThe diluted share base effectively doubled due to a $5.5M raise, contributing to the decision to lower the price target.
Stock PerformanceA premature reverse split in July has led shares to drift downward, and the price target is lowered on a higher estimated share base and lower assumed multiples given weak sentiment.
---
Ownership Overview
―
Insiders
0.11% Mutual Funds
9.55% Other Institutional Investors
90.34% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
EVGN FAQ
What was Evogene’s price range in the past 12 months?
Evogene lowest stock price was $1.44 and its highest was $10.40 in the past 12 months.
What is Evogene’s market cap?
Currently, no data Available
When is Evogene’s upcoming earnings report date?
Evogene’s upcoming earnings report date is Mar 06, 2025 which is in 103 days.
How were Evogene’s earnings last quarter?
Evogene released its earnings results on Nov 21, 2024. The company reported -$1.31 earnings per share for the quarter, missing the consensus estimate of -$1.01 by -$0.3.
Is Evogene overvalued?
According to Wall Street analysts Evogene’s price is currently Undervalued.
Does Evogene pay dividends?
Evogene does not currently pay dividends.
What is Evogene’s EPS estimate?
Evogene’s EPS estimate is -$0.6.
How many shares outstanding does Evogene have?
Evogene has 5,365,438 shares outstanding.
What happened to Evogene’s price movement after its last earnings report?
Evogene reported an EPS of -$1.31 in its last earnings report, missing expectations of -$1.01. Following the earnings report the stock price went down -3.03%.
Which hedge fund is a major shareholder of Evogene?
Among the largest hedge funds holding Evogene’s share is ARK Investment Management LLC. It holds Evogene’s shares valued at N/A.
---
Evogene Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (208.64% Upside)
$5.00 (208.64% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.8%
Last 30 Days ▲ 11.8%
Last 30 Days ▲ 11.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-72.81%
12-Months-Change
Fundamentals
Return on Equity
-331.94%
Trailing 12-Months
Asset Growth
-30.53%
Trailing 12-Months
Company Description
Evogene
Evogene Ltd. operates as a plant genomics company. It utilizes a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity. It also offers a solution for crop productivity improvement through biotechnology and breeding using a technology infrastructure that is based on deep scientific understanding of plant genomics and proprietary computational capabilities. The company was founded by Amir Barzilay and Hagai Karchi in 2002 and is headquartered in Rehovot, Israel.
---
EVGN Stock 12 Month Forecast
Average Price Target
$5.00
▲(208.64% Upside)
Technical Analysis
Best Analysts Covering EVGN
1 Year
1 Year Success Rate
1/16 ratings generated profit
1 Year Average Return
-56.14%
reiterated a buy rating 2 days ago
Copying Ben Klieve's trades and holding each position for 1 Year would result in 6.25% of your transactions generating a profit, with an average return of -56.14% per trade.
---